Dendrite to Provide Outlook on December 14, 2006

  
    
  
  
    
      Dendrite International, Inc. (NASDAQ: DRTE) a leading provider of 
      pharmaceutical industry solutions, today announced that the Company 
      plans to provide its revenue and E.P.S outlook for the fourth quarter of 
      2006 and full year 2007 on Thursday, December 14, 2006 after close of 
      market. A press release will be issued, followed by a conference call at 
      4:30 pm EST that day.
    
    
      Investors may access a live simulcast of the call, which will include a 
      speaker-guided presentation, by visiting the Investors' Highlights 
      section of www.dendrite.com. 
      Investors and analysts may also dial [phone] (United 
      States) or [phone] (International) with an access code of 86594407 
      to participate in the conference call.
    
    
      Information on how to access a webcast replay of the call will also be 
      available at www.dendrite.com in 
      the Investors' Highlights section for up to 30 days following the call. 
      In addition, investors may call [phone] (United States) or (617) 
      801-6888 (International); access code is 22101533 for an 
      audio only replay of the call. A copy of the presentation will also be 
      available on the Company’s website.
    
    
      About Dendrite
    
    
      Founded in 1986, Dendrite International (NASDAQ: DRTE) enables sales, 
      marketing, clinical and compliance solutions for the global 
      pharmaceutical industry. The Company’s clients 
      are located in more than 50 countries, and include the world's top 20 
      pharmaceutical companies. For more information, please visit www.dendrite.com.
    
    
      FORWARD LOOKING INFORMATION: This document contains forward-looking 
      statements that may be identified by such forward-looking terminology as 
      "expect," "believe," "anticipate," "will," "intend," "plan," "target," 
      "outlook," "guidance," and similar statements or variations. Such 
      forward-looking statements are based on our current expectations, 
      estimates, assumptions and projections and involve significant risks and 
      uncertainties, including risks which may result from our dependence on 
      the pharmaceutical industry; our fixed expenses in relation to 
      fluctuating revenues and variations in customers' budget cycles; 
      dependence on certain major customers, including the risk associated 
      with our largest customer's plans to transition a significant portion of 
      its U.S. sales force effectiveness services needs; fluctuations in 
      quarterly revenues due to lengthy sales and implementation cycles; our 
      ability to successfully implement our Operational Effectiveness program 
      and to achieve the cost savings in the amounts and time periods expected 
      or budgeted; changes in demand for our products and services 
      attributable to any weakness experienced in the economy or mergers, 
      acquisitions and consolidations in the pharmaceutical industry; risks 
      associated with foreign currency fluctuations as they affect our 
      non-U.S. operations; risks associated with our expanded international 
      operations and our ability to adopt and respond successfully to the 
      unique risks involved in our non-U.S. operations; any difference between 
      estimated and actual stock option expense; and risks associated with 
      reviewing strategic options and with any transaction occurring or being 
      consummated at any subsequent time. Other important factors that should 
      be reviewed and carefully considered are included in the Company's 10-K 
      under "Factors That May Affect Future Results" and its 10-Qs and other 
      reports filed with the SEC. Actual results may differ materially. The 
      Company assumes no obligation for updating any such forward-looking 
      statements to reflect actual results, changes in expectations or 
      assumptions or other changes affecting such forward-looking statements, 
      even if such results or changes make it clear that any such projected 
      results will not be achieved. Any outlook and other forward-looking 
      information is as of the date of this release only. At any such time in 
      the future as the Company may provide revenue, earnings and other 
      outlook information, prior related outlook should no longer be 
      considered current. Our outlook and other forward-looking information do 
      not take into account or reflect any possible future acquisitions, 
      dispositions or similar transactions which may occur.